• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form EFFECT filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

    4/18/25 12:15:04 AM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CANF alert in real time by email
    Notice of Effectiveness
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Notice of Effectiveness
    Effectiveness Date: April 17, 2025
    Accession Number: 0001213900-25-031575
    Submission Type: POS AM
    CIK: 0001536196
    Company Name: Can-Fite BioPharma Ltd.
    File Number: 333-259085
    Get the next $CANF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CANF

    DatePrice TargetRatingAnalyst
    6/24/2021$5.00Buy
    Aegis Capital
    More analyst ratings

    $CANF
    SEC Filings

    See more
    • SEC Form 424B5 filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

      424B5 - Can-Fite BioPharma Ltd. (0001536196) (Filer)

      5/9/25 4:30:39 PM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

      6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)

      5/5/25 8:10:01 AM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

      EFFECT - Can-Fite BioPharma Ltd. (0001536196) (Filer)

      4/18/25 12:15:04 AM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CANF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital initiated coverage on Can Fite Biofarma with a new price target

      Aegis Capital initiated coverage of Can Fite Biofarma with a rating of Buy and set a new price target of $5.00

      6/24/21 10:10:03 AM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CANF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

      SC 13G/A - Can-Fite BioPharma Ltd. (0001536196) (Subject)

      11/14/24 4:48:49 PM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel)

      SC 13G - Can-Fite BioPharma Ltd. (0001536196) (Subject)

      2/14/24 3:32:17 PM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Can-Fite Biopharma Ltd Sponsored ADR (Israel) (Amendment)

      SC 13G/A - Can-Fite BioPharma Ltd. (0001536196) (Subject)

      2/14/22 3:23:08 PM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CANF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis

      Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, today announced that, it has raised $175 million in funding to date. These funds have enabled the advancement of its lead drug candidates, Namodenoson and Piclidenoson, into pivotal Phase III studies for liver cancer and psoriasis, respectively. Can-Fite is a recognized leader in the development of small-molecule therapeutics targeting the A3 adenosine receptor (A3AR), which is highly expressed in both inflammatory and cancer cells. Namodenoson, an orally bioavailab

      5/5/25 8:00:00 AM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

      Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that leading Medical Centers in the US are approaching the FDA, asking for compassionate use approval to treat patients with pancreatic carcinoma with the company oncological drug Namodenoson. Namodenoson has recently received FDA approval for its first single-patient compassionate use treatment, marking a significant milestone in its clinical journey. This approval has sparked growing interest from oncologists at leading U.S. medical center

      4/17/25 8:55:00 AM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

      RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases ("Can-Fite" or the "Company"), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 of the Company's American Depositary Shares ("ADSs"), at a purchase price of $1.20 per ADS, in a registered direct offering. The offering is expected to close on or about April 15, 2025, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross

      4/14/25 2:28:14 PM ET
      $CANF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CANF
    Financials

    Live finance-specific insights

    See more
    • 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Can-Fite BioPharma Ltd. (NYSE:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:SXTP: https://www.redchip.com/assets/access/sxtp_accessCANF: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on

      11/22/24 9:00:00 AM ET
      $CANF
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE:OSTX) and Can-Fite BioPharma Ltd. (NYSE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:OS Therapies: https://www.redchip.com/assets/access/ostx_accessCan-Fite: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Paul Romness, Chairman and CEO of OS Therapies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate

      8/9/24 9:00:00 AM ET
      $CANF
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo

      5/10/24 9:00:00 AM ET
      $CANF
      $NTRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties